Stockscreener 앱 받기
1.00
0.00%
0.00
전일 마감가:
$1.00
열려 있는:
$1.01
하루 거래량:
488.59K
Relative Volume:
0.18
시가총액:
$67.75M
수익:
-
순이익/손실:
$-46.12M
주가수익비율:
-1.1571
EPS:
-0.8642
순현금흐름:
$-41.02M
1주 성능:
-3.85%
1개월 성능:
-3.85%
6개월 성능:
+17.65%
1년 성능:
-60.78%
1일 변동 폭
$1.00
$1.06
1주일 범위
$0.9966
$1.095
52주 변동 폭
$0.7113
$2.77
Inflarx N V Stock (IFRX) Company Profile
IFRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IFRX
Inflarx N V
|
1.00 | 67.75M | 0 | -46.12M | -41.02M | -0.8642 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Inflarx N V Stock (IFRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-03 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-02 | 재개 | H.C. Wainwright | Buy |
| 2025-05-29 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-04-05 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-02-28 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-10-28 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2021-03-11 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-11-06 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2020-10-08 | 개시 | H.C. Wainwright | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-04-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-06-05 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2019-06-05 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-05 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2019-06-05 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2019-06-05 | 다운그레이드 | SunTrust | Buy → Hold |
| 2019-01-29 | 개시 | Robert W. Baird | Outperform |
| 2018-12-10 | 개시 | Credit Suisse | Outperform |
| 2018-07-13 | 개시 | BMO Capital Markets | Outperform |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-28 | 개시 | SunTrust | Buy |
| 2018-02-08 | 개시 | B. Riley FBR, Inc. | Buy |
모두보기
Inflarx N V 주식(IFRX)의 최신 뉴스
Bank Watch: Is Montauk Renewables Inc a potential multi baggerWatch List & Low Drawdown Momentum Ideas - baoquankhu1.vn
Bull Run: Why InflaRx N.V. (IF0) stock could rally stronglyJuly 2025 Levels & Weekly High Potential Stock Alerts - Bộ Nội Vụ
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Pullback Watch: Will InflaRx NV stock recover faster than market2025 Key Highlights & Daily Profit Maximizing Tips - Bộ Nội Vụ
Is InflaRx N.V. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - Улправда
Why InflaRx N.V. stock remains on buy listsWeekly Investment Recap & Reliable Breakout Stock Forecasts - Улправда
How InflaRx N.V. stock valuations compare to rivalsInflation Watch & Technical Pattern Recognition Alerts - Улправда
InflaRx Cuts Workforce and Refocuses Strategy on Lead Drug Izicopan to Extend Cash Runway to 2027 - TipRanks
Will InflaRx N.V. stock recover faster than market2025 Top Gainers & Advanced Swing Trade Entry Alerts - Улправда
Why is InflaRx Stock Falling Today?InflaRx (NASDAQ:IFRX) - Benzinga
InflaRx stock falls after announcing restructuring and pipeline prioritization By Investing.com - Investing.com India
InflaRx stock falls after announcing restructuring and pipeline prioritization - Investing.com
InflaRx to prioritize izicopan development, cuts workforce by 30% - Investing.com South Africa
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - GlobeNewswire
What analysts say about InflaRx NV IF0 stockPrice Support Zones & Follow Top Performers in the Community - earlytimes.in
Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? - RTTNews
InflaRx (IFRX) stock: biotech battleground after a volatile quarter and shifting expectations - AD HOC NEWS
InflaRx NV Is Exploding: Hidden Biotech Underdog or Just Another Hype Trap? - AD HOC NEWS
Raymond James reiterates Outperform rating on Inflarx stock at $9 target - Investing.com
Short Interest in InflaRx N.V. (NASDAQ:IFRX) Increases By 26.7% - MarketBeat
InflaRx reports potential efficacy signals in failed PG drug trial By Investing.com - Investing.com Nigeria
InflaRx (IFRX) Shares Mixed Results from Vilobelimab Phase 3 Trial in Ulcerative PG - parameter.io
InflaRx reveals phase 3 post‑hoc efficacy signals for vilobelimab in pyoderma gangrenosum after trial halt - MSN
Momentum Shift: Is InflaRx NV stock a top pick in earnings seasonLong Setup & Growth-Oriented Investment Plans - Bộ Nội Vụ
InflaRx (NASDAQ:IFRX) Receives Buy Rating from HC Wainwright - MarketBeat
InflaRx Reports Efficacy Signals In Terminated Phase 3 Study Of Vilobelimab In Pyoderma Gangrenosum - Nasdaq
InflaRx Shares In-Dept Analysis About Vilobelimab, Stock Down In Pre-Market - Nasdaq
InflaRx reports potential efficacy signals in failed PG drug trial - Investing.com
InflaRx N.V. Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - marketscreener.com
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - Sahm
Published on: 2025-12-24 04:49:46 - moha.gov.vn
Analysts Set InflaRx N.V. (NASDAQ:IFRX) Price Target at $7.50 - Defense World
Why InflaRx N.V. (IF0) stock trades below fair valuePortfolio Return Summary & Expert Verified Movement Alerts - Улправда
Is InflaRx N.V. stock a buy in volatile marketsTrade Exit Summary & Weekly High Return Stock Forecasts - DonanımHaber
Why InflaRx N.V. stock is a value investor pick2025 Earnings Surprises & AI Powered Trade Plan Recommendations - DonanımHaber
Is InflaRx N.V. stock positioned for digital transformationJuly 2025 Patterns & Low Drawdown Trading Techniques - DonanımHaber
InflaRx N.V. (NASDAQ:IFRX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Understanding IFRX’s book value per share for better investment insights - uspostnews.com
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug - MSN
InflaRx NV Stock Analysis and ForecastStock Split Announcements & Big Gains Low Investment - earlytimes.in
Can Northern Spirits Limited Outperform Index Funds Over the Next 5 YearsAnalyst Downgrades & Small Investment Big Gains - earlytimes.in
InflaRx’s oral C5aR inhibitor receives WHO generic name izicopan By Investing.com - Investing.com South Africa
InflaRx’s oral C5aR inhibitor receives WHO generic name izicopan - Investing.com India
InflaRx Announces International Nonproprietary Name of 'Izicopan” for INF904 - The Manila Times
InflaRx N.V. Announces WHO Grant of International Nonproprietary Name “izicopan” for C5aR Inhibitor INF904 - Quiver Quantitative
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 - Yahoo Finance
Gap Down: Why InflaRx NV stock is a value investor pickMarket Trend Review & Safe Entry Zone Tips - moha.gov.vn
Inflarx N V (IFRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):